BioSpace News Archive

ELITONE® maker Elidah adds Dr. Barbara Levy to Medical Advisory Board.

With thorough precautions to minimize risk of COVID-19, patients can expect safe and personalized care.

Today the K-cosmeceutical company Dermafirm USA, Inc., the U.S. arm of South Korea’s Dermafirm Inc., is officially announcing its U.S. expansion

Access Genetics, LLC dba OralDNA ® Labs announces that FDA has issued an Emergency Use Authorization for its OraRisk ® COVID-19 RT-PCR test. This test is for qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swab and nasal swab specimens collected in universal transport media, and nasal swabs collected

Berkeley Lights, Inc. announced the closing of its initial public offering of 9,315,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 1,215,000 shares of common stock, at a public offering price of $22.00 per share.

Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announces the closing of its global offering of an aggregate of 11,000,000 new ordinary shares,

Successful first half: Sales revenue up 22.0 percent; order intake1 up 34.1 percent; underlying EBITDA1 margin reaches 30.2 percent

Candidates in the LEO PDE4 inhibitor compound series have demonstrated potential to become `best-in-class’ based on Phase 2 studies in psoriasis (oral) and atopic dermatitis (topical)

TCI GENE, a subsidiary of TCI Co., Ltd. that produces the MOHW-certified QVS-96 system delivered to Kunyang Laboratory, CDC, Taiwan, has been registered with U.S. FDA and qualified to sell the fully automated detection integration system in the U.S.

Tubulis announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates and to support the further growth of the company.